Objective:

The article describes Optegra’s expansion of Espansione’s eye-light photobiomodulation treatment for dry AMD across five UK hospitals, including its protocol, eligibility and cited study findings.

Approach:

• Availability: Optegra plans to offer Espansione’s eye-light treatment at five UK hospitals in London, Manchester, Colchester, Bradford and Hampshire.
• Treatment: The non-invasive therapy delivers yellow light at approximately 590 nm and red light at approximately 630 nm through closed eyelids. Both eyes are treated simultaneously in sessions lasting around 12 minutes. The protocol is eight sessions over four weeks; some patients may receive a further six-session cycle approximately four to six months later.
• Eligibility: Treatment is available to people aged 50 or older with confirmed dry AMD, following an assessment for suitability. Patients may be referred by an optometrist or self-refer.

Key Findings:

• The article reports that one cited study found more than 20% of treated patients gained at least five visual-acuity letters after four months.
• Treated eyes in that study had a statistically significant reduction in mean drusen volume compared with sham treatment.
• The article states that further research is needed to establish how durable these effects are and which patients are most likely to benefit.

Interpretation:

Optegra is expanding access to photobiomodulation for dry AMD, for which treatment options for most patients have historically been limited. The article reports findings from a cited study and notes that further research is needed to establish the durability of the effects and identify which patients are most likely to benefit.

Limitations:

• The durability of treatment effects and the patient groups most likely to benefit remain uncertain, according to the article.

Conclusion:

The treatment is being introduced at five Optegra hospitals as a non-invasive option for eligible patients with dry AMD.

Sources:

• Article context provided by the user